Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
125.42
-1.29 (-1.02%)
At close: Jun 27, 2025, 4:00 PM
125.42
0.00 (0.00%)
After-hours: Jun 27, 2025, 5:59 PM EDT
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,800 employees as of December 31, 2024. The number of employees increased by 400 or 28.57% compared to the previous year.
Employees
1,800
Change (1Y)
400
Growth (1Y)
28.57%
Revenue / Employee
$1,340,333
Profits / Employee
$169,889
Market Cap
12.41B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,800 | 400 | 28.57% |
Dec 31, 2023 | 1,400 | 200 | 16.67% |
Dec 31, 2022 | 1,200 | 300 | 33.33% |
Dec 31, 2021 | 900 | 55 | 6.51% |
Dec 31, 2020 | 845 | 145 | 20.71% |
Dec 31, 2019 | 700 | 115 | 19.66% |
Dec 31, 2018 | 585 | 185 | 46.25% |
Dec 31, 2017 | 400 | 204 | 104.08% |
Dec 31, 2016 | 196 | 76 | 63.33% |
Dec 31, 2015 | 120 | 26 | 27.66% |
Dec 31, 2014 | 94 | 13 | 16.05% |
Dec 31, 2013 | 81 | 3 | 3.85% |
Dec 31, 2012 | 78 | 7 | 9.86% |
Dec 31, 2011 | 71 | 5 | 7.58% |
Dec 31, 2010 | 66 | 1 | 1.54% |
Dec 31, 2009 | 65 | -60 | -48.00% |
Dec 31, 2008 | 125 | -10 | -7.41% |
Dec 31, 2007 | 135 | -132 | -49.44% |
Dec 31, 2006 | 267 | -321 | -54.59% |
Dec 31, 2005 | 588 | 203 | 52.73% |
Dec 31, 2004 | 385 | 40 | 11.59% |
Dec 31, 2003 | 345 | 69 | 25.00% |
Dec 31, 2002 | 276 | 54 | 24.32% |
Dec 31, 2001 | 222 | 34 | 18.09% |
Dec 31, 2000 | 188 | 37 | 24.50% |
Dec 31, 1999 | 151 | 2 | 1.34% |
Dec 31, 1998 | 149 | 41 | 37.96% |
Dec 31, 1997 | 108 | 5 | 4.85% |
Dec 31, 1996 | 103 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NBIX News
- 1 day ago - Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea - PRNewsWire
- 8 days ago - Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia - PRNewsWire
- 19 days ago - Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer - PRNewsWire
- 25 days ago - Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - GlobeNewsWire
- 26 days ago - Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia - PRNewsWire
- 4 weeks ago - Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - GlobeNewsWire
- 4 weeks ago - Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - PRNewsWire
- 6 weeks ago - Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting - PRNewsWire